Erkang Pharmaceutical announced that the controlling shareholder Shuai Fangwen's holdings reduction plan expires. From April 23, 2026 to July 22, 2026, the holdings were reduced by 10.776 million shares through centralized bidding, accounting for 0.52% of the total share capital, and the average holdings reduction price was 4.38 yuan/share. After this holdings reduction, Shuai Fangwen held 843 million shares, accounting for 40.86% of the total share capital.

Erkang Pharmaceutical announced that the controlling shareholder Shuai Fangwen's holdings reduction plan expires. From April 23, 2026 to July 22, 2026, the holdings were reduced by 10.776 million shares through centralized bidding, accounting for 0.52% of the total share capital, and the average holdings reduction price was 4.38 yuan/share. After this holdings reduction, Shuai Fangwen held 843 million shares, accounting for 40.86% of the total share capital.